Lyell Immunopharma (NASDAQ:LYEL) Earns Buy Rating from Analysts at Stifel Nicolaus

Key Points

• Stifel Nicolaus initiated coverage of Lyell Immunopharma with a “buy” rating and a $36 price target, implying 167.66% upside from the stock’s $13.45 opening price.
• Analyst sentiment is generally favorable, with MarketBeat reporting a “Moderate Buy” consensus and an average price target of $42, despite ratings ranging from strong buy to sell.
• Lyell remains a clinical-stage biotechnology company developing engineered T-cell therapies for solid tumors; it reported a quarterly loss of $1.10 per share and had 66.05% institutional ownership.

Research analysts at Stifel Nicolaus assumed coverage on shares of Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) in a research note issued on Thursday,Benzinga reports. The brokerage set a "buy" rating and a $36.00 price target on the stock. Stifel Nicolaus' price objective suggests a potential upside of 167.66% from the company's current price.

A number of other analysts have also recently weighed in on LYEL. Robert W. Baird set a $49.00 price target on shares of Lyell Immunopharma and gave the company an "outperform" rating in a report on Thursday, April 30th. Wall Street Zen upgraded Lyell Immunopharma from a "sell" rating to a "hold" rating in a research note on Sunday, May 10th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Lyell Immunopharma in a research note on Friday, July 17th. HC Wainwright reaffirmed a "buy" rating and issued a $45.00 price target on shares of Lyell Immunopharma in a report on Tuesday, June 9th. Finally, Zacks Research upgraded shares of Lyell Immunopharma from a "strong sell" rating to a "hold" rating in a research note on Monday, May 18th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $42.00.

Lyell Immunopharma Stock Down 1.1%

LYEL opened at $13.45 on Thursday. Lyell Immunopharma has a 52-week low of $9.28 and a 52-week high of $45.00. The business has a fifty day moving average of $13.55 and a 200 day moving average of $19.10. The stock has a market cap of $329.52 million, a P/E ratio of -0.97 and a beta of -0.04.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last issued its earnings results on Wednesday, May 6th. The company reported ($1.10) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($1.10). Lyell Immunopharma had a negative net margin of 794,858.12% and a negative return on equity of 85.71%. The company had revenue of $0.00 million for the quarter, compared to analysts' expectations of $0.00 million. Equities analysts anticipate that Lyell Immunopharma will post -7.69 EPS for the current fiscal year.

Institutional Trading of Lyell Immunopharma

Hedge funds have recently modified their holdings of the stock. Bank of America Corp DE lifted its holdings in Lyell Immunopharma by 314.2% in the first quarter. Bank of America Corp DE now owns 33,321 shares of the company's stock valued at $668,000 after acquiring an additional 25,276 shares during the period. Renaissance Technologies LLC grew its stake in shares of Lyell Immunopharma by 194.8% during the 1st quarter. Renaissance Technologies LLC now owns 116,411 shares of the company's stock worth $2,335,000 after purchasing an additional 76,921 shares during the period. Walleye Capital LLC acquired a new position in shares of Lyell Immunopharma in the 1st quarter valued at $445,000. Dimensional Fund Advisors LP purchased a new stake in Lyell Immunopharma during the first quarter worth $959,000. Finally, Invesco Ltd. purchased a new stake in Lyell Immunopharma during the fourth quarter worth $3,036,000. Hedge funds and other institutional investors own 66.05% of the company's stock.

Lyell Immunopharma Company Profile

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company's approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company's pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source